{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T21:45:37Z","timestamp":1775511937662,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.cellsig.2021.109938","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:45:18Z","timestamp":1612313118000},"page":"109938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer"],"prefix":"10.1016","volume":"81","author":[{"given":"Mumin Alper","family":"Erdogan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Ashour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkan","family":"Yuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kivanc","family":"Gorgulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Ozpolat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cellsig.2021.109938_bb0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.cellsig.2021.109938_bb0010","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.cellsig.2021.109938_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/GCO.0b013e3282f2b124","article-title":"Cancer antigen 125 and prognosis","volume":"20","author":"Hogdall","year":"2008","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"Suppl. 3","key":"10.1016\/j.cellsig.2021.109938_bb0020","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/ijgc-00009577-200511001-00015","article-title":"New tumor markers: CA125 and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8580","key":"10.1016\/j.cellsig.2021.109938_bb0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(88)90351-0","article-title":"Multimodal approach to screening for ovarian cancer","volume":"1","author":"Jacobs","year":"1988","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.cellsig.2021.109938_bb0030","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.cellsig.2021.109938_bb0035","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1471-0528.2005.00572.x","article-title":"Symptoms associated with diagnosis of ovarian cancer: a systematic review","volume":"112","author":"Bankhead","year":"2005","journal-title":"BJOG."},{"key":"10.1016\/j.cellsig.2021.109938_bb0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"issue":"17","key":"10.1016\/j.cellsig.2021.109938_bb0045","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic oncology group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2021.109938_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"10 suppl","key":"10.1016\/j.cellsig.2021.109938_bb0055","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/JCO.2003.02.553","article-title":"Developmental chemotherapy and management of recurrent ovarian cancer","volume":"21","author":"Bookman","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.cellsig.2021.109938_bb0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2021.109938_bb0065","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nature Rev. Disease Primers"},{"issue":"33","key":"10.1016\/j.cellsig.2021.109938_bb0070","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.cellsig.2021.109938_bb0075","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.cellsig.2021.109938_bb0080","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.cellsig.2021.109938_bb0085","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2021.109938_bb0090","doi-asserted-by":"crossref","first-page":"17299","DOI":"10.1016\/S0021-9258(18)45377-X","article-title":"Identification of the major Mr 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2","volume":"262","author":"Nairn","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2021.109938_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbior.2014.04.003","article-title":"Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles","volume":"55","author":"Kenney","year":"2014","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.cellsig.2021.109938_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041171","article-title":"Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer","volume":"7","author":"Tekedereli","year":"2012","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.cellsig.2021.109938_bb0105","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2217\/nnm-2019-0132","article-title":"Eukaryotic elongation factor-2 Kinase (EF2K) promotes BRCA1-mutated breast cancer tumorigenesis, angiogenesis and progression by inducing multiple oncogenic pathways","volume":"14","author":"Asik","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.cellsig.2021.109938_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2018.07.027","article-title":"Elongation Factor-2 kinase (EF2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer","volume":"124","author":"Bircan","year":"2018","journal-title":"Lung Cancer, V"},{"key":"10.1016\/j.cellsig.2021.109938_bb0115","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4161\/auto.29164","article-title":"Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells","volume":"10","author":"Xie","year":"2014","journal-title":"Autophagy."},{"key":"10.1016\/j.cellsig.2021.109938_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbrc.2011.09.038","article-title":"Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression","volume":"414","author":"Zhang","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellsig.2021.109938_bb0125","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4161\/auto.6083","article-title":"Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells","volume":"4","author":"Akar","year":"2008","journal-title":"Autophagy"},{"key":"10.1016\/j.cellsig.2021.109938_bb0130","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4161\/auto.4349","article-title":"PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells","volume":"3","author":"Ozpolat","year":"2007","journal-title":"Autophagy"},{"issue":"7","key":"10.1016\/j.cellsig.2021.109938_bb0135","article-title":"Therapeutic silencing of nanoliposomal EF2K by siRNA in primary and metastic breast cancer in animal models","volume":"7","author":"Tekedereli","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2021.109938_bb0140","first-page":"17","article-title":"Cell sensitivity assays: clonogenic assay","volume":"28","author":"Plumb","year":"1999","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.cellsig.2021.109938_bb0145","first-page":"97","article-title":"Tumor cell invasion assays","volume":"294","author":"Shaw","year":"2005","journal-title":"Methods Mol. Biol."},{"issue":"15","key":"10.1016\/j.cellsig.2021.109938_bb0150","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","article-title":"Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery","volume":"65","author":"Landen","year":"2005","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.cellsig.2021.109938_bb0155","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1158\/1078-0432.CCR-06-0021","article-title":"Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy","volume":"12","author":"Halder","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2021.109938_bb0160","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.119.3.493","article-title":"Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation","volume":"119","author":"Gavrieli","year":"1992","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.cellsig.2021.109938_bb0165","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s10495-012-0713-6","article-title":"Integrin\/Fak\/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes","volume":"17","author":"Beausejour","year":"2012","journal-title":"Apoptosis"},{"key":"10.1016\/j.cellsig.2021.109938_bb0170","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1158\/1078-0432.CCR-04-0621","article-title":"Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice","volume":"10","author":"Yezhelyev","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2021.109938_bb0175","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1158\/1535-7163.MCT-09-1212","article-title":"Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis","volume":"9","author":"Nagaraj","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cellsig.2021.109938_bb0180","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","article-title":"Src protein-tyrosine kinase structure and regulation","volume":"324","author":"Roskoski","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"39","key":"10.1016\/j.cellsig.2021.109938_bb0185","doi-asserted-by":"crossref","first-page":"63466","DOI":"10.18632\/oncotarget.11525","article-title":"Helfman Integrin \u03b21, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer","volume":"7","author":"Choi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellsig.2021.109938_bb0190","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.cellsig.2021.109938_bb0195","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0002-9440(10)61708-7","article-title":"New insights into the role of nuclear factor-\u03baB in cell growth regulation","volume":"159","author":"Chen","year":"2001","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.cellsig.2021.109938_bb0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3892\/etm.2011.194","article-title":"Cyclin D1 predicts the prognosis of advanced serous ovarian cancer","volume":"2","author":"Hashimoto","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.cellsig.2021.109938_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BST0340001","article-title":"The life and death of translation elongation factor 2","volume":"34","author":"Jorgensen","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.cellsig.2021.109938_bb0210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.bjc.6690012","article-title":"Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer","volume":"79","author":"Parmer","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellsig.2021.109938_bb0215","first-page":"1403","article-title":"Role of calmodulin-dependent phosphorylation of elongation factor 2 in the proliferation of rat glial cells","volume":"5","author":"Bagaglio","year":"1994","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.cellsig.2021.109938_bb0220","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0167-4889(95)00084-6","article-title":"Phosphorylation of eukaryotic elongation factor 2 in differentiating and proliferating HL-60 cells","volume":"1268","author":"Nilsson","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cellsig.2021.109938_bb0225","first-page":"327","article-title":"Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells","volume":"8","author":"Parmer","year":"1997","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.cellsig.2021.109938_bb0230","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.cellsig.2021.109938_bb0235","first-page":"1387","article-title":"Extracellular matrix as target for antitumor therapy","volume":"8","author":"Harisi","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.cellsig.2021.109938_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.12361","article-title":"Elongation factor-2 kinase regulates TG2\/\u03b21 integrin\/Src\/uPAR pathway and epithelialmesenchymal transition mediating pancreatic cancer cells invasion","author":"Ashour","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cellsig.2021.109938_bb0245","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.cellbio.13.1.513","article-title":"Cellular functions regulated by Src family kinases","volume":"13","author":"Thomas","year":"1997","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.cellsig.2021.109938_bb0250","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.bjc.6600710","article-title":"Expression level of integrin alpha 5 on tumor cells affects the rate of metastasis to the kidney","volume":"27","author":"Tani","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellsig.2021.109938_bb0255","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/0008-5472.CAN-10-2889","article-title":"eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206","volume":"71","author":"Cheng","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2021.109938_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009715","article-title":"Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition","volume":"5","author":"Cheng","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2021.109938_bb0265","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4161\/auto.22801","article-title":"Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells","volume":"9","author":"Cheng","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.cellsig.2021.109938_bb0270","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cell.2013.04.055","article-title":"The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation","volume":"153","author":"Leprivier","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2021.109938_bb0275","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/0008-5472.CAN-05-1554","article-title":"Elongation factor-2 kinase regulates autophagy in human glioblastoma cells","volume":"66","author":"Wu","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2021.109938_bb0280","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1158\/0008-5472.CAN-08-2872","article-title":"Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2021.109938_bb0285","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.18632\/oncotarget.7672","article-title":"FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells","volume":"7","author":"Hamurcu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellsig.2021.109938_bb0290","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s10495-014-1019-7","article-title":"Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer","volume":"19","author":"Fu","year":"2014","journal-title":"Apoptosis"},{"key":"10.1016\/j.cellsig.2021.109938_bb0295","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1021\/bi201787p","article-title":"Investigating the kinetic mechanism of inhibition of elongation factor 2 kinase by NH125: evidence of a common in vitro Artifact","volume":"51","author":"Devkota","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.cellsig.2021.109938_bb0300","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2796.2009.02191.x","article-title":"Nanomedicine based approaches for the delivery of siRNA in cancer","volume":"267","author":"Ozpolat","year":"2010","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cellsig.2021.109938_bb0305","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature02870","article-title":"Unlocking the potential of the human genome with RNA interference","volume":"431","author":"Hannon","year":"2004","journal-title":"Nature"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656821000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656821000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:02:01Z","timestamp":1760266921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656821000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":61,"alternative-id":["S0898656821000267"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2021.109938","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2021.109938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109938"}}